FIELD: pharmaceutical chemistry. SUBSTANCE: HMH CoA reductase (e.g. pravastatin, lovastatin, symvastatin, fluvastatin, rivastatin, or atorvastation) and one or more insulin-sensitizing agents (e.g. troglytasone, pioglytasone, englytasone, BRZ-49653, 5-(-2-(4-2'- pyridylphenyl)ethylenediaminooxy)ethoxy)benzyl)thiazolidine-2,4-dione, 5-(4-(5-methoxy-3-methylimidazo[5,4-b] pyridin-2- ylmethoxy)benzyl)thiazolidine-2,4-dione or hydrochloride thereof, 5-(4- (6-methoxy-1-methylbenzylimidazol-2-ylmethoxy)benzyl)thiazolidine- 2,4-dione, 5-(4-(1-methylbenzimidazol-2-ylmethoxy)benzyl)thiazolidine- 2,4-dione, and 5-(4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2- ylmethoxy)benzyl)thiazolidine-2,4-dione) are injected to treat arteriosclerosis and/or xanthoma. Invention also provides packaged pharmaceutical preparation containing above-defined combination. EFFECT: increased treatment efficiency. 78 cl, 10 tbl, 6 ex
